Ivan S. Serov
Ivan S. Serov has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anna V. Aksenova
Chazov National Medical Research Center of Cardiology
4 shared publications - Olga A. Belova
Cardiology Dispensary
4 shared publications - Svetlana A. Rachkova
Cardiological dispensary
4 shared publications - Irina Evgenievna Chazova
E.I. Chazov National Medical Research Center Of Cardiology
3 shared publications - Raia S. Makarian
Chazov National Medical Research Center of Cardiology
2 shared publications Irina E. Chazova
Chazov National Medical Research Center of Cardiology
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (8) , 472-477
Arterial hypertension and bronchial asthma: phenotype, cardiovascular complications, and independent predictors – an analysis of 57,396 patients from a hypertension registry
Background. The combination of arterial hypertension (AH) and bronchial asthma (BA) presents a complex clinical challenge that notably elevates cardiovascular risk. Real-world data are scarce regarding the phenotype and incidence of cardiovascular complications within this patient population. Aim. To investigate the prevalence of cardiovascular risk factors and comorbidities in patients with AH, taking into account the presence of BA, as recorded in the national hypertension registry. Materials and methods. Retrospective analysis of a hypertension registry: 56,784 AH patients without BA and 612 with AH+BA. Demographic and anthropometric parameters and comorbidity prevalence were compared. Odds ratios (OR) were adjusted for sex and age. Results. BA prevalence was 1.1%. The AH+BA phenotype was characterized by female predominance (71.4% vs 59.4%; p0.001), older age (65.0 years vs 62.7 years; p0.001), higher BMI (29.4 kg/m2 vs 28.5 kg/m2; p=0.002), and abdominal obesity (53.7% vs 39.0%; p=0.003). BA was associated with higher rates of coronary artery disease – CAD (56.2% vs 41.2%), chronic heart failure – CHF (68.8% vs 48.6%), and atrial fibrillation – AF (10.1% vs 4.3%; all p0.001). After adjustment, BA remained an independent predictor of CAD (OR 2.02, 95% confidence interval – CI 1.71–2.40), CHF (OR 2.47, 95% CI 2.07–2.96), and AF (OR 2.49, 95% CI 1.88–3.23). No association with stroke was found. Conclusion. The comorbidity of BA and AH is associated with a distinct phenotype (older woman with abdominal obesity). BA is an independent predictor of CAD, CHF, and AF, mandating active cardiovascular screening.
- 18 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (8) , 472-477
Open AccessArterial hypertension and bronchial asthma: phenotype, cardiovascular complications, and independent predictors – an analysis of 57,396 patients from a hypertension registry
Background. The combination of arterial hypertension (AH) and bronchial asthma (BA) presents a complex clinical challenge that notably elevates cardiovascular risk. Real-world data are scarce regarding the phenotype and incidence of cardiovascular complications within this patient population. Aim. To investigate the prevalence of cardiovascular risk factors and comorbidities in patients with AH, taking into account the presence of BA, as recorded in the national hypertension registry. Materials and methods. Retrospective analysis of a hypertension registry: 56,784 AH patients without BA and 612 with AH+BA. Demographic and anthropometric parameters and comorbidity prevalence were compared. Odds ratios (OR) were adjusted for sex and age. Results. BA prevalence was 1.1%. The AH+BA phenotype was characterized by female predominance (71.4% vs 59.4%; p0.001), older age (65.0 years vs 62.7 years; p0.001), higher BMI (29.4 kg/m2 vs 28.5 kg/m2; p=0.002), and abdominal obesity (53.7% vs 39.0%; p=0.003). BA was associated with higher rates of coronary artery disease – CAD (56.2% vs 41.2%), chronic heart failure – CHF (68.8% vs 48.6%), and atrial fibrillation – AF (10.1% vs 4.3%; all p0.001). After adjustment, BA remained an independent predictor of CAD (OR 2.02, 95% confidence interval – CI 1.71–2.40), CHF (OR 2.47, 95% CI 2.07–2.96), and AF (OR 2.49, 95% CI 1.88–3.23). No association with stroke was found. Conclusion. The comorbidity of BA and AH is associated with a distinct phenotype (older woman with abdominal obesity). BA is an independent predictor of CAD, CHF, and AF, mandating active cardiovascular screening.
- 1 April 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (1)
Clinical Profile and Antihypertensive Treatment Patterns in Patients with Comorbid Hypertension and Type 2 Diabetes Mellitus: Insights from the National Hypertension Registry
Relevance. The high prevalence of diabetes mellitus among patients with hypertension and the increased risk of cardiovascular complications necessitate a more detailed study of the characteristics of this patient group in order to optimize their management approach. Objective. To identify clinical features of comorbid patients with hypertension and diabetes mellitus, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of absence of diabetes mellitus. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R foundation for Statistical Computing, Vienna, Austria). Results. Type 2 diabetes mellitus (T2DM) was detected in 15.3% of patients with hypertension (HTN). The group of patients with HTN and type 2 diabetes mellitus was predominantly represented by women (66.6%), who most often had risk factors such as obesity (55.4%) and low physical activity (40.3%). Compared to hypertensive patients without T2DM, those with hypertension and T2DM had significantly higher rates of chronic heart failure (64.4% vs 46.0%), coronary artery disease (54.9% vs 39.0%), chronic kidney disease (35.8% vs 28.3%), and prior cerebrovascular events (7.0% vs 4.1%). Patients with hypertension combined with T2DM demonstrated greater treatment resistance, with more frequent prescriptions of angiotensin receptor blockers (24.7% vs 16.7%), beta-blockers (59.5% vs 51.5%), and calcium channel blockers (22.3% vs 15.1%). Conclusions. The identified changes reflect an additional negative impact of type 2 diabetes on the course of hypertension and the development of cardiovascular complications. Due to the high burden of cardiac and non-cardiac pathologies in this patient group, a more aggressive and multicomponent approach to therapy is required. The obtained results emphasize the need for the development of comprehensive programs for prevention, early diagnosis, and an individualized approach to prescribing therapy. The combination of hypertension and type 2 diabetes in the Russian federation necessitates an interdisciplinary approach with an emphasis on controlling metabolic parameters and the early prevention of complications.
- 1 April 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (1)
Clinical Profile and Antihypertensive Treatment Patterns in Patients with Comorbid Hypertension and Type 2 Diabetes Mellitus: Insights from the National Hypertension Registry
Relevance. The high prevalence of diabetes mellitus among patients with hypertension and the increased risk of cardiovascular complications necessitate a more detailed study of the characteristics of this patient group in order to optimize their management approach. Objective. To identify clinical features of comorbid patients with hypertension and diabetes mellitus, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of absence of diabetes mellitus. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R foundation for Statistical Computing, Vienna, Austria). Results. Type 2 diabetes mellitus (T2DM) was detected in 15.3% of patients with hypertension (HTN). The group of patients with HTN and type 2 diabetes mellitus was predominantly represented by women (66.6%), who most often had risk factors such as obesity (55.4%) and low physical activity (40.3%). Compared to hypertensive patients without T2DM, those with hypertension and T2DM had significantly higher rates of chronic heart failure (64.4% vs 46.0%), coronary artery disease (54.9% vs 39.0%), chronic kidney disease (35.8% vs 28.3%), and prior cerebrovascular events (7.0% vs 4.1%). Patients with hypertension combined with T2DM demonstrated greater treatment resistance, with more frequent prescriptions of angiotensin receptor blockers (24.7% vs 16.7%), beta-blockers (59.5% vs 51.5%), and calcium channel blockers (22.3% vs 15.1%). Conclusions. The identified changes reflect an additional negative impact of type 2 diabetes on the course of hypertension and the development of cardiovascular complications. Due to the high burden of cardiac and non-cardiac pathologies in this patient group, a more aggressive and multicomponent approach to therapy is required. The obtained results emphasize the need for the development of comprehensive programs for prevention, early diagnosis, and an individualized approach to prescribing therapy. The combination of hypertension and type 2 diabetes in the Russian federation necessitates an interdisciplinary approach with an emphasis on controlling metabolic parameters and the early prevention of complications.
- Open Access
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 59-68
Clinical portrait and distinctive features of antihypertensive therapy in comorbid patients with Hypertension and gout according to the national hypertension registry
Relevance. The increasing prevalence of gout among patients with hypertension and other cardio-vascular diseases, as well as harmful influence on cardio- vascular risk warrant the need for more scrupulous examination and multidisciplinary approach to hypertensive patients with gout. Aim. To identify clinical features of comorbid patients with hypertension and gout, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of gout. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R Foundation for Statistical Computing, Vienna, Austria). Results. 0,6% of hypertensive patients had gout. Patients with gout more frequently had chronic heart failure (63,9%), ischemic heart disease (52,5%), chronic kidney disease (39,8%), transient ischemic attack (3,1%). The majority of patients were men (65,1%) with such risk factors as obesity (52,5%), smoking (71,8%), alcohol intake (47,3%), sedentary lifestyle (37,8%) and poor diet (48,9%). They were also more frequently diagnosed with diabetes mellitus – 26,2% and liver cirrhosis (1,5%). The specific treatment features of this group of patients include more frequent therapy with angiotensin receptor blockers (30,9%) and loop diuretics – 13,6%. Conclusion. Despite relatively low prevalence of gout in general population of patients with hypertension, this comorbid group of patients has high cardio- vascular risk and is characterised by exceptionally high presence of additional cardiac and non-cardiac pathologies. Distinctive features of treatment reflect the necessity of adaptive approach in order to meet the additional needs of these patients, including treatment of chronic heart failure and chronic kidney disease. Results of this study emphasise the necessity to implement a multidisciplinary approach in management of these patients, involving the aggressive modification of any risk factors and selection of a rational pharmacological treatment, based on concomitant pathology.
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 59-68
Open AccessClinical portrait and distinctive features of antihypertensive therapy in comorbid patients with Hypertension and gout according to the national hypertension registry
Relevance. The increasing prevalence of gout among patients with hypertension and other cardio-vascular diseases, as well as harmful influence on cardio- vascular risk warrant the need for more scrupulous examination and multidisciplinary approach to hypertensive patients with gout. Aim. To identify clinical features of comorbid patients with hypertension and gout, as well as to assess their treatment. Materials and methods. 57396 ambulatory patients from the national registry of hypertension were included in this study. They were divided into 2 groups based on the presence of gout. The assessment of social and anthropometric factors, medical history, modifiable cardio-vascular risk factors was conducted. Statistical analysis was done using R 4.3.3 environment (R Foundation for Statistical Computing, Vienna, Austria). Results. 0,6% of hypertensive patients had gout. Patients with gout more frequently had chronic heart failure (63,9%), ischemic heart disease (52,5%), chronic kidney disease (39,8%), transient ischemic attack (3,1%). The majority of patients were men (65,1%) with such risk factors as obesity (52,5%), smoking (71,8%), alcohol intake (47,3%), sedentary lifestyle (37,8%) and poor diet (48,9%). They were also more frequently diagnosed with diabetes mellitus – 26,2% and liver cirrhosis (1,5%). The specific treatment features of this group of patients include more frequent therapy with angiotensin receptor blockers (30,9%) and loop diuretics – 13,6%. Conclusion. Despite relatively low prevalence of gout in general population of patients with hypertension, this comorbid group of patients has high cardio- vascular risk and is characterised by exceptionally high presence of additional cardiac and non-cardiac pathologies. Distinctive features of treatment reflect the necessity of adaptive approach in order to meet the additional needs of these patients, including treatment of chronic heart failure and chronic kidney disease. Results of this study emphasise the necessity to implement a multidisciplinary approach in management of these patients, involving the aggressive modification of any risk factors and selection of a rational pharmacological treatment, based on concomitant pathology.
- Open Access
- 31 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (7) , 538-544
Clinical portrait and features of antihypertensive therapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease according to the national hypertension registry
Background. Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) are the two leading causes of death in the world. Studies show a close mutually aggravating relationship between arterial hypertension (AH) and COPD. Antihypertensive therapy in patients with AH and COPD has a number of features, aiming to reduce the risk of developing cardiovascular complications and mortality from CVD without worsening lung function. Aim. To analyze the data of patients with AH and COPD included in the national registry to determine the burden of CVD risk factors, concomitant cardiovascular, cerebrovascular diseases and chronic kidney disease, obesity, diabetes mellitus, gout and characteristics of antihypertensive therapy. Materials and methods. A comparative analysis of patients of the hypertension registry (conducted in outpatient clinics) was performed depending on the presence (n=3323) or absence (n=54073) of chronic obstructive pulmonary disease. Statistical analysis of the obtained data were performed using the R 4.3.3 statistical computing environment (R Foundation for Statistical Computing, Vienna, Austria). Results. The prevalence of COPD in patients with hypertension was 5.8% (3323 cases). The presence of COPD in patients with hypertension, regardless of gender and age, was statistically significantly associated with higher odds of having coronary artery disease [odds ratio (OR) 2.21, 95% confidence interval (CI) 2.06–2.38; p0.001], a history of myocardial infarction (OR 1.73, 95% CI 1.59–1.87; p0.001), chronic heart failure (OR 1.95, 95% CI 1.82–2.1; p0.001), a history of acute cerebrovascular accident (OR 1.25, 95% CI 1.07–1.46; p=0.004), transient ischemic attack (OR 2.9, 95% CI 2.31–3.59; p0.001), atrial fibrillation (OR 1.68, 95% CI 1.45–1.93; p0.001). Patients with hypertension and COPD more often received drugs from the group of angiotensin-II receptor antagonists than patients with hypertension without COPD (22.7% vs 17.7%). The prescription of drugs from the group of beta-blockers in patients with hypertension and COPD was lower by 4%. Cardiovascular risk factors, comorbidities such as diabetes mellitus, gout, obstructive sleep apnea in patients with hypertension and COPD are more common. Conclusion. Patients with COPD and hypertension have a higher incidence of risk factors, CVD and comorbid pathologies. They require closer attention during examination and during the selection of antihypertensive therapy. In patients with hypertension and COPD, angiotensin-converting-enzyme inhibitors and beta-blockers are prescribed less frequently than in patients with hypertension without COPD due to possible side effects and contraindications.
- 31 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (7) , 538-544
Open AccessClinical portrait and features of antihypertensive therapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease according to the national hypertension registry
Background. Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) are the two leading causes of death in the world. Studies show a close mutually aggravating relationship between arterial hypertension (AH) and COPD. Antihypertensive therapy in patients with AH and COPD has a number of features, aiming to reduce the risk of developing cardiovascular complications and mortality from CVD without worsening lung function. Aim. To analyze the data of patients with AH and COPD included in the national registry to determine the burden of CVD risk factors, concomitant cardiovascular, cerebrovascular diseases and chronic kidney disease, obesity, diabetes mellitus, gout and characteristics of antihypertensive therapy. Materials and methods. A comparative analysis of patients of the hypertension registry (conducted in outpatient clinics) was performed depending on the presence (n=3323) or absence (n=54073) of chronic obstructive pulmonary disease. Statistical analysis of the obtained data were performed using the R 4.3.3 statistical computing environment (R Foundation for Statistical Computing, Vienna, Austria). Results. The prevalence of COPD in patients with hypertension was 5.8% (3323 cases). The presence of COPD in patients with hypertension, regardless of gender and age, was statistically significantly associated with higher odds of having coronary artery disease [odds ratio (OR) 2.21, 95% confidence interval (CI) 2.06–2.38; p0.001], a history of myocardial infarction (OR 1.73, 95% CI 1.59–1.87; p0.001), chronic heart failure (OR 1.95, 95% CI 1.82–2.1; p0.001), a history of acute cerebrovascular accident (OR 1.25, 95% CI 1.07–1.46; p=0.004), transient ischemic attack (OR 2.9, 95% CI 2.31–3.59; p0.001), atrial fibrillation (OR 1.68, 95% CI 1.45–1.93; p0.001). Patients with hypertension and COPD more often received drugs from the group of angiotensin-II receptor antagonists than patients with hypertension without COPD (22.7% vs 17.7%). The prescription of drugs from the group of beta-blockers in patients with hypertension and COPD was lower by 4%. Cardiovascular risk factors, comorbidities such as diabetes mellitus, gout, obstructive sleep apnea in patients with hypertension and COPD are more common. Conclusion. Patients with COPD and hypertension have a higher incidence of risk factors, CVD and comorbid pathologies. They require closer attention during examination and during the selection of antihypertensive therapy. In patients with hypertension and COPD, angiotensin-converting-enzyme inhibitors and beta-blockers are prescribed less frequently than in patients with hypertension without COPD due to possible side effects and contraindications.